Prevention of Cytomegalovirus Infection in Solid Organ Transplant Recipients : Guidelines by the Korean Society of Infectious Diseases and the Korean Society for Transplantation
Copyright © 2024 by The Korean Society of Infectious Diseases, Korean Society for Antimicrobial Therapy, and The Korean Society for AIDS..
Cytomegalovirus (CMV) is the most important opportunistic viral pathogen in solid organ transplant (SOT) recipients. The Korean guideline for the prevention of CMV infection in SOT recipients was developed jointly by the Korean Society for Infectious Diseases and the Korean Society of Transplantation. CMV serostatus of both donors and recipients should be screened before transplantation to best assess the risk of CMV infection after SOT. Seronegative recipients receiving organs from seropositive donors face the highest risk, followed by seropositive recipients. Either antiviral prophylaxis or preemptive therapy can be used to prevent CMV infection. While both strategies have been demonstrated to prevent CMV infection post-transplant, each has its own advantages and disadvantages. CMV serostatus, transplant organ, other risk factors, and practical issues should be considered for the selection of preventive measures. There is no universal viral load threshold to guide treatment in preemptive therapy. Each institution should define and validate its own threshold. Valganciclovir is the favored agent for both prophylaxis and preemptive therapy. The evaluation of CMV-specific cell-mediated immunity and the monitoring of viral load kinetics are gaining interest, but there was insufficient evidence to issue recommendations. Specific considerations on pediatric transplant recipients are included.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:56 |
|---|---|
| Enthalten in: |
Infection & chemotherapy - 56(2024), 1 vom: 23. März, Seite 101-121 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Huh, Kyungmin [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cytomegalovirus |
|---|
| Anmerkungen: |
Date Revised 06.04.2024 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3947/ic.2024.0016 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370173341 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370173341 | ||
| 003 | DE-627 | ||
| 005 | 20240406232358.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240327s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3947/ic.2024.0016 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1367.xml |
| 035 | |a (DE-627)NLM370173341 | ||
| 035 | |a (NLM)38527780 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Huh, Kyungmin |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Prevention of Cytomegalovirus Infection in Solid Organ Transplant Recipients |b Guidelines by the Korean Society of Infectious Diseases and the Korean Society for Transplantation |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 06.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Copyright © 2024 by The Korean Society of Infectious Diseases, Korean Society for Antimicrobial Therapy, and The Korean Society for AIDS. | ||
| 520 | |a Cytomegalovirus (CMV) is the most important opportunistic viral pathogen in solid organ transplant (SOT) recipients. The Korean guideline for the prevention of CMV infection in SOT recipients was developed jointly by the Korean Society for Infectious Diseases and the Korean Society of Transplantation. CMV serostatus of both donors and recipients should be screened before transplantation to best assess the risk of CMV infection after SOT. Seronegative recipients receiving organs from seropositive donors face the highest risk, followed by seropositive recipients. Either antiviral prophylaxis or preemptive therapy can be used to prevent CMV infection. While both strategies have been demonstrated to prevent CMV infection post-transplant, each has its own advantages and disadvantages. CMV serostatus, transplant organ, other risk factors, and practical issues should be considered for the selection of preventive measures. There is no universal viral load threshold to guide treatment in preemptive therapy. Each institution should define and validate its own threshold. Valganciclovir is the favored agent for both prophylaxis and preemptive therapy. The evaluation of CMV-specific cell-mediated immunity and the monitoring of viral load kinetics are gaining interest, but there was insufficient evidence to issue recommendations. Specific considerations on pediatric transplant recipients are included | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Cytomegalovirus | |
| 650 | 4 | |a Organ transplantation | |
| 650 | 4 | |a Prevention | |
| 700 | 1 | |a Lee, Sang-Oh |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Jungok |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Su Jin |e verfasserin |4 aut | |
| 700 | 1 | |a Choe, Pyoeng Gyun |e verfasserin |4 aut | |
| 700 | 1 | |a Kang, Ji-Man |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Jaeseok |e verfasserin |4 aut | |
| 700 | 1 | |a Sung, Heungsup |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Si-Ho |e verfasserin |4 aut | |
| 700 | 1 | |a Moon, Chisook |e verfasserin |4 aut | |
| 700 | 1 | |a Seok, Hyeri |e verfasserin |4 aut | |
| 700 | 1 | |a Shi, Hye Jin |e verfasserin |4 aut | |
| 700 | 1 | |a Wi, Yu Mi |e verfasserin |4 aut | |
| 700 | 1 | |a Jeong, Su Jin |e verfasserin |4 aut | |
| 700 | 1 | |a Park, Wan Beom |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Youn Jeong |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Jongman |e verfasserin |4 aut | |
| 700 | 1 | |a Ahn, Hyung Joon |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Nam Joong |e verfasserin |4 aut | |
| 700 | 1 | |a Peck, Kyong Ran |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Myoung Soo |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Sang Il |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Infection & chemotherapy |d 2013 |g 56(2024), 1 vom: 23. März, Seite 101-121 |w (DE-627)NLM232968403 |x 2093-2340 |7 nnns |
| 773 | 1 | 8 | |g volume:56 |g year:2024 |g number:1 |g day:23 |g month:03 |g pages:101-121 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3947/ic.2024.0016 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 56 |j 2024 |e 1 |b 23 |c 03 |h 101-121 | ||